Summary
This article discusses how Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising treatment for type 2 diabetes (T2D) patients, especially those with chronic kidney disease (CKD), showing benefits beyond glucose and weight control, including potential cardiovascular and kidney protective effects.
GLP-1RAs and Kidney Protection in Type 2 Diabetes
Highlights
Chronic Kidney Disease in Type 2 Diabetes
Chronic kidney disease (CKD) is a prevalent complication among individuals with type 2 diabetes (T2D).
Benefits of GLP-1RAs
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective in improving glycemic control and reducing body weight in T2D patients. Some GLP-1RAs also reduce cardiovascular (CV) event risk in high-risk individuals.
Kidney-Protective Effects
Beyond their known benefits, GLP-1RAs are also suggested to have kidney-protective effects, which could be significant for T2D patients with CKD.